Merck protease inhibitor available to persons with CD4 count 50 or less--must register by August 11.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002986:Clinical Trials as Topic; D004345:Drug Industry; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000600:supply & distribution* / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir; D018579:Patient Selection; D011725:Pyridines / Q000494:pharmacology / Q000600:supply & distribution* / Q000627:therapeutic use; D014481:United States
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D019469:Indinavir